Bedell Frazier Investment Counselling’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-46,767
Closed -$3.6M 75
2020
Q2
$3.6M Sell
46,767
-23,480
-33% -$1.8M 1.45% 26
2020
Q1
$5.25M Sell
70,247
-6,281
-8% -$434K 2.46% 15
2019
Q4
$4.85M Hold
76,528
1.94% 25
2019
Q3
$4.85M Sell
76,528
-7,480
-9% -$489K 1.89% 26
2019
Q2
$5.68M Sell
84,008
-4,565
-5% -$300K 2.07% 25
2019
Q1
$5.76M Buy
88,573
+13,950
+19% +$927K 2.27% 20
2018
Q4
$4.67M Sell
74,623
-35,464
-32% -$2.48M 1.99% 20
2018
Q3
$8.5M Sell
110,087
-608
-0.5% -$45.9K 2.35% 17
2018
Q2
$7.84M Buy
110,695
+1,191
+1% +$84.1K 2.3% 21
2018
Q1
$8.26M Buy
109,504
+10,379
+10% +$825K 2.92% 12
2017
Q4
$7.1M Buy
99,125
+29,536
+42% +$2.24M 2.64% 19
2017
Q3
$5.64M Sell
69,589
-1,377
-2% -$105K 2.6% 21
2017
Q2
$5.02M Buy
70,966
+10,745
+18% +$715K 1.83% 30
2017
Q1
$4.09M Buy
60,221
+3,631
+6% +$255K 1.55% 31
2016
Q4
$4.05M Buy
56,590
+3,125
+6% +$232K 1.59% 33
2016
Q3
$4.23M Buy
+53,465
New +$4.34M 1.75% 27

Other funds holding GILD

Bedell Frazier Investment Counselling's GILD Position: Q3 2020 in Review

Bedell Frazier Investment Counselling sold out of Gilead Sciences (GILD) in Q3 2020, closing a stake of 46,767 shares — an estimated $3.6M sold.

Bedell Frazier Investment Counselling first reported a position in GILD in Q3 2016 and held it in 16 quarters. The position peaked at $8.5M in Q3 2018. 1,539 funds tracked by Wall St. Rank hold GILD as of Q3 2020.

  • Bedell Frazier Investment Counselling reported no remaining Gilead Sciences position as of Q3 2020 after selling out during the quarter.
  • Bedell Frazier Investment Counselling sold 46,767 Gilead Sciences shares in Q3 2020, an estimated $3.6M.
  • Bedell Frazier Investment Counselling first reported a position in Gilead Sciences in Q3 2016 and held it in 16 quarters.
  • Bedell Frazier Investment Counselling's Gilead Sciences position peaked at $8.5M in Q3 2018.
  • 1,539 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2020.

Based on Bedell Frazier Investment Counselling's 13F filing for Q3 2020, filed 5 Nov 2020.